Chemotherapy News and Research

Latest Chemotherapy News and Research

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Cancer treatments alter the landscape of genetic mutations in healthy body tissues

Cancer treatments, including chemotherapy and radiotherapy, give a growth advantage to cells with particular genetic changes in healthy tissue, new research finds.

11 Sep 2026

Childhood chemotherapy leaves lasting DNA damage in healthy cells

Chemotherapy, which saves the lives of many children with cancer, causes previously unknown DNA alterations in the liver and leaves genetic footprints in other healthy cells as well.

10 Sep 2026

Breast cancer AI test finds no single chatbot excels across every measure

Researchers compared five large language models on breast cancer health information using 90 knowledge questions, 10 clinical cases, and 20 common patient concerns, with all prompts submitted in simplified Chinese. The models performed strongly on standardized knowledge overall, but differed in linguistic complexity and expert-rated completeness, readability, helpfulness, correctness, and safety.

10 Sep 2026

Study reveals hidden DNA damage from childhood chemotherapy

The amount of DNA damage caused by certain chemotherapies used to effectively treat childhood cancer has been revealed, along with a hidden impact on the liver, paving the way for future research into new ways to mitigate these impacts.

10 Sep 2026

Shortages of crucial cancer medications continue to impact US healthcare

Today, the National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-published updated data on the current impact of generic cancer medication shortages in the United States.

10 Sep 2026

Yourgene Health launches Insight DPYD assay (IVDR)

Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the commercial launch of its In Vitro Diagnostic Regulation (IVDR)-certified Yourgene® Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets.

From Yourgene Health 9 Sep 2026

New genetic map helps track aggressive prostate cancer development

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why the disease develops or why some men live with it for years while in others it progresses aggressively.

9 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026